SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announces FDA approval of Utebzi (tebipenem pivoxil), the first…

GSK plc · 6-K filed Jun 17, 2026 at 12:02 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jun 17, 2026 at 12:02 ET

GSK announces FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults. The approval is based on the PIVOT-PO phase III trial demonstrating non-inferiority to intravenous imipenem-cilastatin. This expands GSK's anti-infectives portfolio and addresses a significant unmet need, though near-term financial impact is modest relative to GSK's $106.5B market cap.

  • FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis in adults with limited/no oral alternatives.
  • First and only oral carbapenem antibiotic approved in the US.
  • PIVOT-PO trial showed 58.5% overall success rate for tebipenem pivoxil vs 60.2% for IV imipenem-cilastatin (adjusted difference -1.3%; 95% CI -7.5%, 4.8%).
  • Product anticipated to be available to US patients by end of 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access